A PSEN1 genetic test sequences one gene — PSEN1 — to look for rare mutations that cause early-onset familial Alzheimer's disease, a form of dementia that typically starts before age 60 to 65. It does not measure risk for the common, late-onset Alzheimer's that affects most older adults, and even a clear result leaves real questions unanswered. When a person already has dementia symptoms and a doctor orders this test, the goal is usually to confirm or rule out an inherited cause running in the family. Lab Tests Online UK notes that PSEN1 is the most common of the three known early-onset familial Alzheimer's genes, accounting for up to roughly 70% of cases — but the test's reach stops at that specific genetic question.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Test Actually Looks For
- Why a Negative Result Doesn't Close the Question
- Why a Positive Result Still Leaves Questions Open
- What the Test Can't Predict About Symptoms
- What to Do With the Result
- Frequently Asked Questions
What the Test Actually Looks For
PSEN1 testing reads the DNA sequence of the PSEN1 gene for pathogenic variants — mutation types already linked to early-onset familial Alzheimer's disease, or EOFAD. Lab Tests Online UK explains that EOFAD generally starts before age 60 to 65, much earlier than typical Alzheimer's. The gene is inherited in an autosomal dominant pattern.
That means a parent who carries a pathogenic PSEN1 variant passes it to each child with a 50% probability, according to Lab Tests Online UK. In a person who is already symptomatic, a positive result points to a high likelihood of EOFAD, usually arriving near the age of onset already seen in other affected relatives. This test is targeted, not a general screen. Clinical guidance limits its appropriate use to symptomatic adults with a strong family history of early-onset dementia, or to asymptomatic relatives of someone already confirmed to carry a PSEN1 variant — not to the general population and not as a check for ordinary late-onset Alzheimer's, per Lab Tests Online UK.
Why a Negative Result Doesn't Close the Question
A negative PSEN1 result does not rule out a genetic cause of early-onset dementia. ARUP Laboratories reports that its early-onset Alzheimer's sequencing panel, which includes PSEN1, has a clinical sensitivity of only 60–80% for familial early-onset Alzheimer's, meaning a meaningful share of true genetic cases will not be caught by the panel (ARUP Laboratories sample report). Part of that gap comes from PSEN2, a related gene often tested alongside PSEN1 on the same panel.
ARUP notes that PSEN2 shows reduced penetrance — some carriers never develop the disease at all — which complicates interpretation even when a variant is found elsewhere on the panel. For families with a clear pattern of early-onset dementia across generations, a negative PSEN1 (and panel) result is informative but not definitive. It narrows the explanation without eliminating every inherited possibility.
Why a Positive Result Still Leaves Questions Open
Even a "positive" PSEN1 finding can carry its own uncertainty. A 2021 reclassification study applying standard ACMG-AMP criteria to previously reported PSEN1 variants found that 94.91% were confirmed as pathogenic or likely pathogenic — but 5.09% remained variants of uncertain significance, unable to be definitively tied to disease, according to Frontiers in Aging Neuroscience. Registry data shows the same pattern in practice.
Among 46 people in the Dominantly Inherited Alzheimer Network registry with a coding variant in APP, PSEN1, or PSEN2, 39 carried known pathogenic mutations, 6 carried variants of unknown significance, and 1 was classified only as a risk factor — not a confirmed cause (DIAN Expansion Registry report, 2018, via pub.dzne.de). Confirming a pathogenic variant also doesn't pin down when symptoms will start. A 2025 analysis in Brain catalogued 550 variants across APP, PSEN1, and PSEN2; 279 were pathogenic or likely pathogenic, but age-at-onset estimates existed for only 227 of those, so even a confirmed pathogenic PSEN1 variant often cannot be matched to a precise predicted onset age (McDade, Llibre-Guerra et al., Brain, 2025).
What the Test Can't Predict About Symptoms
PSEN1 testing identifies the genetic cause; it does not forecast how the disease will unfold. The gene carries more severe disease on average than the other EOFAD genes — mutation carriers show an average onset age of 43.3 years, plus or minus 8 years, earlier and more aggressive than PSEN2 mutations or APP mutations and duplications, per a case-literature synthesis from pathologytestsexplained.org.au. The same mutation can behave very differently between relatives.
Case literature on the Cys263Trp variant describes one carrier with early onset at age 45, marked by attention deficits, spatial disorientation, psychiatric symptoms, and parkinsonism — while relatives carrying the identical variant developed typical late-onset, memory-predominant disease instead, according to a case report via PMC. A 2025 case report illustrates how fast and unpredictably the disease can move. A 47-year-old man with a novel PSEN1 variant progressed rapidly through prosopagnosia, executive dysfunction, seizures, and behavioral disturbance, reaching severe dementia by age 55 despite treatment with cholinesterase inhibitors, memantine, and antipsychotics — a reminder that genetic confirmation says nothing about how well a person will respond to treatment or how quickly the disease will advance (PMC case report).
What to Do With the Result
A PSEN1 result changes how a family understands a dementia diagnosis, but it does not replace clinical judgment about symptoms, treatment, or prognosis. A few practical points follow directly from how the test behaves:.
- A positive result in a symptomatic person supports an EOFAD diagnosis but does not predict which symptoms will dominate or how fast they will progress.
- A negative result does not rule out a genetic cause, given the panel's 60–80% sensitivity for familial early-onset Alzheimer's.
- A variant of uncertain significance is neither a confirmed cause nor a cleared result — it stays open pending further classification.
- Relatives of a confirmed carrier face a 50% inheritance risk per pregnancy, regardless of whether the carrier has symptoms yet.
- The test is not designed for, and should not be used to assess, risk of common late-onset Alzheimer's disease.
Frequently Asked Questions
Does a positive PSEN1 result mean a person will definitely develop dementia?
In a symptomatic person with a family history, a positive result indicates a high likelihood of eventual EOFAD, typically near the onset age seen in affected relatives, according to Lab Tests Online UK.
Can PSEN1 testing tell a family when symptoms will start?
Not reliably. A 2025 Brain analysis found age-at-onset estimates for only 227 of 279 pathogenic or likely pathogenic variants catalogued, so many confirmed carriers have no precise predicted onset age.
Is PSEN1 testing useful for someone with typical late-onset memory loss and no family history?
No. Clinical guidance restricts its use to symptomatic adults with a strong family history of early-onset dementia or relatives of a known carrier, per Lab Tests Online UK.
